Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC. Oberlin O, et al. Among authors: bouvet n. J Clin Oncol. 2012 Jul 10;30(20):2457-65. doi: 10.1200/JCO.2011.40.3287. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665534 Clinical Trial.
Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Stewart RJ, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer RD, Godzinski J, Stevens MC; International Society of Pediatric Oncology. Stewart RJ, et al. Among authors: bouvet n. J Clin Oncol. 2003 Mar 1;21(5):793-8. doi: 10.1200/JCO.2003.06.040. J Clin Oncol. 2003. PMID: 12610176
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O. Stevens MC, et al. Among authors: bouvet n. J Clin Oncol. 2005 Apr 20;23(12):2618-28. doi: 10.1200/JCO.2005.08.130. Epub 2005 Feb 22. J Clin Oncol. 2005. PMID: 15728225 Clinical Trial.
Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology.
Martelli H, Oberlin O, Rey A, Godzinski J, Spicer RD, Bouvet N, Haie-Meder C, Terrier-Lacombe MJ, Sanchez de Toledo J, Spooner D, Sommelet D, Flamant F, Stevens MC. Martelli H, et al. Among authors: bouvet n. J Clin Oncol. 1999 Jul;17(7):2117-22. doi: 10.1200/JCO.1999.17.7.2117. J Clin Oncol. 1999. PMID: 10561266 Review.
Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group.
Orbach D, Mc Dowell H, Rey A, Bouvet N, Kelsey A, Stevens MC. Orbach D, et al. Among authors: bouvet n. Pediatr Blood Cancer. 2011 Dec 15;57(7):1130-6. doi: 10.1002/pbc.23138. Epub 2011 Apr 14. Pediatr Blood Cancer. 2011. PMID: 21495161 Clinical Trial.
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. Le Cesne A, et al. Among authors: bouvet n. Ann Oncol. 2021 Aug;32(8):1034-1044. doi: 10.1016/j.annonc.2021.04.014. Epub 2021 Apr 29. Ann Oncol. 2021. PMID: 33932507 Free article. Clinical Trial.
Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.
Hartl D, Godbert Y, Carrat X, Bardet S, Lasne-Cardon A, Vera P, Ilies E, Zerdoud S, Sarini J, Zalzali M, La Manna L, Schneegans O, Kelly A, Kaufmann P, Rodien P, Brunaud L, Grunenwald S, Housseau E, Laghouati S, Bouvet N, Lecerf E, Hadoux J, Lamartina L, Schlumberger M, Borget I. Hartl D, et al. Among authors: bouvet n. Trials. 2023 Jul 11;24(1):452. doi: 10.1186/s13063-023-07467-x. Trials. 2023. PMID: 37434205 Free PMC article. No abstract available.
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.
Hartl D, Godbert Y, Carrat X, Bardet S, Lasne-Cardon A, Vera P, Ilies E, Zerdoud S, Sarini J, Zalzali M, La Manna L, Schneegans O, Kelly A, Kauffmann P, Rodien P, Brunaud L, Grunenwald S, Housseau E, Laghouati S, Bouvet N, Lecerf E, Hadoux J, Lamartina L, Schlumberger M, Borget I. Hartl D, et al. Among authors: bouvet n. Trials. 2023 Apr 28;24(1):298. doi: 10.1186/s13063-023-07294-0. Trials. 2023. PMID: 37118818 Free PMC article. Clinical Trial.
14 results